Erratum: Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study (The Lancet (2014) 383(9911) (40–47) (S0140673613616128) (10.1016/S0140-6736(13)61612-8));Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: A community study

The Lancet

Volumn 383, Issue 9911, 2014, Pages 40-47

  Daugla, D M ^a   Gami, J P ^a   Gamougam, K ^a   Naibei, N ^a   Mbainadji, L ^a   Narbe M ^a   Toralta, J ^a   Kodbesse, B ^a   Ngadoua, C ^b   Coldiron, M E ^c   Fermon, F ^c   Page, A L ^c   Djingarey, M H ^d   Hugonnet, S ^e   Harrison, O B ^f   Rebbetts, L S ^f   Tekletsion, Y ^f   Watkins, E R ^f   Hill, D ^f   Caugant, D A ^g   Chandramohan, D ⁱ   Hassan King, M ⁱ   Manigart, O ⁱ   Nascimento, M ⁱ   Woukeu, A ⁱ   Trotter, C ^h   Stuart, J M ⁱ   Maiden, M C J ^f   Greenwood, B M ⁱ   more..

^a Centre de Support en Sante International CSSI   (Chad)

^b Ministry of Public Health   (Chad)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d WHO Intercountry Support Team   (Burkina Faso)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATION; CEREBROSPINAL FLUID; CHAD; CHILD; DRUG EFFECT; EPIDEMIC MENINGITIS; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RURAL AREA; SCHOOL CHILD; YOUNG ADULT; AGE DISTRIBUTION; EPIDEMIC; HEALTH SURVEY; HETEROZYGOTE; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; METHODOLOGY; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CARRIER STATE; CHAD; CHILD; CHILD, PRESCHOOL; EPIDEMICS; HUMANS; INCIDENCE; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; POPULATION SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 84892730857     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62737-3     Document Type: Erratum

References (32)

1. Lapeyssonie L. The meningococcal meningitis in Africa. Bull World Health Org 1963; 28: 3-114 (in French).
2. Patterson KD, Hartwig GW. Cerebrospinal meningitis in West Africa and Sudan in the twentieth century. California, LA, USA: Crossroads Press, 1984.
3. Ledentu, Blanchard. Cerebrospinal meningitis in French Equatorial Africa during the first half of 1939. Bull Off Int d'Hyg Publ 1941; 3: 421-30.
4. Sirol J, Lefevre M, Lassalle Y, Lentrade P. Some new aspects of purulent meningitis in Sahelian Africa. Clinical, bacteriological and therapeutic study of 368 cases observed in 1969 at Fort-Lamy (Tchad). Med Tropicale 1969; 29: 443-54 (in French).
5. Garcia V, Morel B, Wadack MA, Banquio M, Moulia-Pelat JP, Richard V. Outbreak of meningitis in the province of Logone occidental (Chad): descriptive study using health ministry data from 1998 to 2001. Bull Soc Path Exot 2004; 97: 183-88 (in French).
6. Bregani ER, Tarsia P, Pujades E, Van Tien T, Arioli M, Ziglioli E. The 2001 meningitis epidemic in south Chad. Minerva Med 2006; 97: 161-73.
7. WHO. Meningitis in Chad, Niger, and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec 2010; 8: 57-63.
8. Riou J-Y, Djibo S, Sangare L, et al. A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995. Bull World Health Org 1996; 74: 181-87.
9. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of the sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005; 43: 5129-35.
10. Caugant DA, Kristiansen PA, Wang X, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012; 7: e46019.
11. Labrie JE 3rd, Keiser PB. Whole cell vaccines for the meningococcus: lessons from an idea for which time has gone. Hum Vaccin 2010; 6: 360-65.
12. Spiegel A, Greindl Y, Lippeveld T, et al. Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N'Djamena (Chad) in 1988. Bull World Health Org 1993; 71: 311-15 (in French).
13. Lengeler C, Kessler W, Daugla D. The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination. Acta Tropica 1995; 59: 211-22.
14. Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health 2013; 17: 1478-91.
15. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364: 2293-304.
16. Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine 2012; 30 (suppl 2): 40-45.
17. Novak RT, Kambou JL, Diomanded́ FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12: 757-64.
18. Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2012; 56: 354-63.
19. Massenet D, Vohod D, Hamadicko H, Caugant DA. Epidemic meningococcal meningitis, Cameroon. Emerg Infect Dis 2011; 17: 2070-02.
20. The MenAfriCar consortium. Meningococcal carriage in the African meningitis belt. Trop Med Int Health 2013; 18: 968-78.
21. Bennett JS, Jolley KA, Earle SG, et al. A genomic approach to bacterial taxonomy: an examination and proposed reclassification of species within the genus Neisseria. Microbiology 2012; 158: 1570-80.
22. Harmsen D, Singer C, Rothgänger J, et al. Diagnostics of neisseriaceae and moraxellaceae by ribosomal DNA sequencing: ribosomal differentiation of medical microorganisms. J Clin Microbiol 2001; 39: 936-42.
23. Claus H, Maiden MC, Maag R, Frosch M, Vogel U. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 2002; 148: 1813-19.
24. Wang X, Theodore MJ, Mair R, et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J Clin Microbiol 2012; 50: 702-08.
25. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, Maiden MC. The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 1994; 12: 253-65.
26. Caugant DA, Maiden MC. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009; 27 (suppl 2): 64-70.
27. Republic of Chad State Office. Ministry of Public Health 2nd Statement from the Government. Jan 21, 2013. http://www. meningvax.org/files/ 2ndstatementMoHChad-21Jan2013.pdf (accessed Aug 16, 2013)
28. Maiden MC, Stuart JM, for the UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 35: 1829-31.
29. Centers for Disease Control and Prevention (CDC). Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 1022-24.
30. Kim SH, Pezzoli L, Yacouba H, et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One 2012; 7: e29116.
31. Caini S, Beck NS, Yacouba H, et al. From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010-January 2012. Vaccine 2013; 31: 1597-603.
32. Altmann D, Aseffa A, Bash M, et al., for the Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine 2013; 31: 1453-57.